Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH – Get Rating) shares shot up 8% during trading on Friday . The stock traded as high as $19.08 and last traded at $19.03. 5,926 shares were traded during trading, a decline of 99% from the average session volume of 956,942 shares. The stock had previously closed at $17.62.
Analyst Ratings Changes
Several equities analysts have recently weighed in on DCPH shares. Stifel Nicolaus increased their price target on Deciphera Pharmaceuticals from $11.00 to $18.00 and gave the company a "hold" rating in a report on Tuesday, September 27th. Piper Sandler increased their price target on Deciphera Pharmaceuticals from $13.00 to $18.00 in a report on Sunday, September 11th. SVB Leerink increased their price target on Deciphera Pharmaceuticals from $21.00 to $25.00 and gave the company an "outperform" rating in a report on Monday, September 12th. Cowen started coverage on Deciphera Pharmaceuticals in a report on Monday, August 29th. They set an "outperform" rating and a $25.00 price target on the stock. Finally, Cowen started coverage on Deciphera Pharmaceuticals in a report on Monday, August 29th. They set an "outperform" rating and a $25.00 price target on the stock. Two equities research analysts have rated the stock with a sell rating, five have assigned a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of "Hold" and an average target price of $18.70.
Get Deciphera Pharmaceuticals alerts:Deciphera Pharmaceuticals Trading Up 5.0 %
The firm has a market cap of $1.24 billion, a PE ratio of -4.32 and a beta of 1.00. The stock has a 50 day simple moving average of $16.44 and a 200-day simple moving average of $12.99.
Deciphera Pharmaceuticals (NASDAQ:DCPH – Get Rating) last issued its quarterly earnings results on Thursday, August 4th. The company reported ($0.60) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.65) by $0.05. Deciphera Pharmaceuticals had a negative return on equity of 74.37% and a negative net margin of 231.99%. The business had revenue of $32.49 million during the quarter, compared to analyst estimates of $30.11 million. During the same quarter in the prior year, the business posted ($1.21) EPS. Deciphera Pharmaceuticals's revenue for the quarter was up 37.8% compared to the same quarter last year. On average, equities research analysts expect that Deciphera Pharmaceuticals, Inc. will post -2.5 EPS for the current year.Institutional Investors Weigh In On Deciphera Pharmaceuticals
Institutional investors have recently bought and sold shares of the business. US Bancorp DE grew its position in shares of Deciphera Pharmaceuticals by 100.6% during the second quarter. US Bancorp DE now owns 4,052 shares of the company's stock valued at $53,000 after purchasing an additional 2,032 shares in the last quarter. Amalgamated Bank purchased a new position in shares of Deciphera Pharmaceuticals during the first quarter valued at about $57,000. Lazard Asset Management LLC purchased a new position in shares of Deciphera Pharmaceuticals during the first quarter valued at about $57,000. Denali Advisors LLC grew its position in shares of Deciphera Pharmaceuticals by 33.9% during the first quarter. Denali Advisors LLC now owns 7,900 shares of the company's stock valued at $73,000 after purchasing an additional 2,000 shares in the last quarter. Finally, Los Angeles Capital Management LLC purchased a new position in shares of Deciphera Pharmaceuticals during the first quarter valued at about $98,000. Hedge funds and other institutional investors own 72.29% of the company's stock.
About Deciphera Pharmaceuticals
(Get Rating)
Deciphera Pharmaceuticals, Inc, a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies in the United States and internationally. Its lead drug candidate is QINLOCK used for the treatment of gastrointestinal stromal tumors (GIST), as well as in INTRIGUE Phase 3 study to treat second-line GIST.
Further Reading
- Get a free copy of the StockNews.com research report on Deciphera Pharmaceuticals (DCPH)
- EV Battery Maker Freyr Set For Major Global Expansion
- MarketBeat: Week in Review 9/26 – 9/30
- This Is A Memorable Time To Buy Into Micron Technology
- Let Paychex Stock Work Hard For You
- Declining Profits Challenge the CarMax Value Proposition
Receive News & Ratings for Deciphera Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Deciphera Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.